

Poliomyelitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/P8791547D0FEEN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: P8791547D0FEEN

Abstracts

The 7 major poliomyelitis markets are expected to exhibit a CAGR of 5.04% during 2024-2034.

The poliomyelitis market has been comprehensively analyzed in IMARC's new report titled "Poliomyelitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Poliomyelitis, commonly known as polio, refers to a highly infectious viral disease caused by the poliovirus. It primarily affects young children, but people of all ages can be impacted. Most individuals infected with the poliovirus experience no symptoms or only mild flu-like indications. However, in a small percentage of cases, the virus invades the nervous system, leading to more severe symptoms. This form of polio is characterized by muscle weakness or paralysis, often asymmetrically affecting the limbs. Various other indications may include loss of reflexes, muscle pain, fatigue, headache, fever, stiffness in the neck and back, etc. In rare cases, the virus can affect the muscles involved in breathing, potentially leading to respiratory distress or failure. Diagnosing poliomyelitis typically consists of a combination of clinical evaluation, laboratory testing, and epidemiological investigation. Initially, a healthcare professional will assess the patient's symptoms, medical history, and potential exposure to the poliovirus. A physical examination may reveal muscle weakness, decreased reflexes, or abnormal sensations. Several laboratory tests, such as viral culture or polymerase chain reaction (PCR), are used to detect the presence of the poliovirus in throat swabs, stool samples, or cerebrospinal fluid.

The increasing cases of poor sanitation, inadequate hygiene practices, and close personal contact, which can contribute to the transmission of the poliovirus, are primarily driving the poliomyelitis market. Moreover, the widespread adoption of non-

opioid analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), for reducing inflammation as well as relieving pain in patients without the risk of opioid-related side effects or dependency is further bolstering the market growth. Apart from this, the inflating application of various assistive devices, including braces, orthotics, canes, crutches, wheelchairs, etc., for enhancing mobility and independence for individuals suffering from polio is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of complementary therapies, such as acupuncture, acupressure, massage therapy, etc., since they can help to promote relaxation, improve blood circulation, and decrease muscle tension, is creating a positive outlook for the market. Additionally, the introduction of new vaccine formulations, including the inactivated polio vaccine (IPV) and the novel oral polio vaccine (nOPV), which aid in reducing the risk of vaccine-associated paralytic polio while maintaining high immunogenicity, is expected to drive the poliomyelitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the poliomyelitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for poliomyelitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the poliomyelitis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the poliomyelitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the poliomyelitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current poliomyelitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the poliomyelitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the poliomyelitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the poliomyelitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of poliomyelitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of poliomyelitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of poliomyelitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with poliomyelitis across the seven major markets?

What is the size of the poliomyelitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of poliomyelitis?

What will be the growth rate of patients across the seven major markets?

Poliomyelitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for poliomyelitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the poliomyelitis market?

What are the key regulatory events related to the poliomyelitis market?

What is the structure of clinical trial landscape by status related to the poliomyelitis market?

What is the structure of clinical trial landscape by phase related to the poliomyelitis market?

What is the structure of clinical trial landscape by route of administration related to the poliomyelitis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 POLIOMYELITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 POLIOMYELITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 POLIOMYELITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 POLIOMYELITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 POLIOMYELITIS - UNMET NEEDS

10 POLIOMYELITIS - KEY ENDPOINTS OF TREATMENT

11 POLIOMYELITIS - MARKETED PRODUCTS

- 11.1 List of Poliomyelitis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Pediarix (DTaP-hepatitis B-poliovirus vaccine) - GlaxoSmithKline
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Vaxelis (Hib-DTaP-Hepatitis-B-Poliovirus-vaccine) - Merck
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Kinrix (DTaP-poliovirus vaccine paediatric) - GlaxoSmithKline
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Quadracel (DTaP poliovirus vaccine paediatric) - Sanofi
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Pentacel (Hib-DTaP-poliovirus vaccine) - Sanofi
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 POLIOMYELITIS - PIPELINE DRUGS

- 12.1 List of Poliomyelitis Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Drug Name – Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. POLIOMYELITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. POLIOMYELITIS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 POLIOMYELITIS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Poliomyelitis - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Poliomyelitis - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Poliomyelitis - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Poliomyelitis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Poliomyelitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Poliomyelitis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Poliomyelitis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Poliomyelitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Poliomyelitis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Poliomyelitis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)

- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Poliomyelitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Poliomyelitis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Poliomyelitis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Poliomyelitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Poliomyelitis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Poliomyelitis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Poliomyelitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Poliomyelitis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Poliomyelitis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Poliomyelitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Poliomyelitis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Poliomyelitis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Poliomyelitis - Access and Reimbursement Overview

16 POLIOMYELITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 POLIOMYELITIS MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 POLIOMYELITIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Poliomyelitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/P8791547D0FEEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P8791547D0FEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

